Preparation for the treatment of atopic dermatitis

Abstract

The invention relates to an oil-in-water emulsion (O / W emulsion) containing 70-80 wt.% water, based on the total weight of the preparation, 5-10 wt.% lipids, based on the total weight of the preparation, 2-8 wt.% glycerol, based on the total weight of the preparation, one or more emulsifiers, and one or more polymers, for the cosmetic and / or dermatological treatment of atopic dermatitis.

Description

[0001] Description

[0002] Preparation for the treatment of atopic dermatitis

[0003] The present invention relates to an oil-in-water emulsion (O / W emulsion) containing 70 to 80 wt% water, 5 to 10 wt% lipids, 2 to 8 wt% glycerin, one or more emulsifiers and one or more polymers, for the cosmetic and / or dermatological treatment of atopic dermatitis.

[0004] Atopic dermatitis is known as a type I allergic reaction reacting to IgE. Various topical preparations for the therapeutic treatment of atopic skin disease have been developed to date, which include a compound with an activity that inhibits PCA reactions reacting to IgE as an active ingredient.

[0005] In practical application, however, none is known to be adequately effective, while steroids, such as adrenocortical hormones, continue to make up the bulk of external preparations for the therapeutic treatment of atopic skin diseases.

[0006] Although the steroids currently used for atopic dermatitis, which are used for skin diseases and other skin diseases, have excellent therapeutic efficacy when used over a long period of time, systemic side effects are produced, including the functional suppression of the hypothalamus, pituitary gland and adrenocortex.

[0007] Despite being used as topical preparations, they frequently cause additional local side effects in the form of skin symptoms, such as exacerbation of skin infections and acne-like symptoms associated with adrenocortical hormones. Reports have also surfaced of scarring, age spots, and freckles during administration, as well as post-treatment problems.

[0008] Due to the problems mentioned above, immunosuppressants, antihistamines, and antiallergics, among others, were developed as therapeutic agents for atopic dermatitis. However, immunosuppressants involve problems such as exacerbating bacterial skin infections, and antihistamines involve problems of adverse side effects, such as drug rash.

[0009] Regarding atopic dermatitis, the cause of which has not yet been identified, patients with symptoms and their family members suffer from itching. Skin itching, or pruritus, is a common dermatological symptom that can cause significant distress in both humans and animals.

[0010] For the treatment of atopic dermatitis, preparations with a high lipid content (50% by weight and more) are also used according to current best practices. Lipids are generally believed to reduce inflammation in the skin. However, lipid-rich preparations have the disadvantage of being difficult to spread on the skin. This is particularly problematic in areas with dense hair growth. Furthermore, these preparations have an unappealing texture. They are described as greasy, sticky, or greasy. These negative effects are especially pronounced at higher ambient temperatures, for example, in summer.

[0011] It was therefore the object of the present invention to develop a preparation suitable for the cosmetic and / or dermatological treatment of atopic dermatitis which no longer has these disadvantages.

[0012] This problem is surprisingly solved by an oil-in-water emulsion (O / W emulsion) containing

[0013] 70 to 80% by weight, based on the total weight of the preparation, water,

[0014] 5 to 10% by weight, based on the total weight of the preparation, lipids; 2 to 8% by weight, based on the total weight of the preparation, glycerin; one or more emulsifiers; one or more polymers; for the cosmetic and / or dermatological treatment of atopic dermatitis.

[0015] Such compound preparations are known to those skilled in the art. However, it was surprising and unforeseeable for them that such a preparation, containing only small amounts of anti-inflammatory lipids, could effectively treat skin areas affected by atopic dermatitis.

[0016] It is advantageous for the emulsions according to the invention if sodium cetearyl sulfate (INCI: Sodium Cetearyl Sulfate) is used as an emulsifier. In such a case, it is preferred according to the invention if sodium cetearyl sulfate is used in a concentration of 0.03 to 0.08 wt%, based on the total weight of the preparation.

[0017] Advantageous embodiments of the present invention are also characterized in that one or more compounds selected from the group of gums (INGI: Gums) are used as polymers.

[0018] It has proven to be preferable according to the invention if xanthan gum (INCI: Xanthan Gum) and / or gellan gum (INCI: Gellan Gum) are used as gums. The combination of both compounds is particularly preferred.

[0019] According to the invention, it is advantageous if the preparation contains gums in a total concentration of 0.1 to 0.5 wt%, based on the total weight of the preparation.

[0020] The preferred concentration of xanthan gum according to the invention is 0.2 to 0.4 wt%, based on the total weight of the preparation.

[0021] The preferred concentration of gellan gum according to the invention is 0.05 to 0.15 wt%, based on the total weight of the preparation.

[0022] Furthermore, advantageous embodiments according to the invention are characterized in that one or more starches are used as polymers. It is preferred according to the invention if one or more starches are used as polymers in a total concentration of 1 to 2% by weight, based on the total weight of the preparation.

[0023] Furthermore, according to the invention, it is preferred if tapioca starch (INCI: Tapioca Starch) is used as the starch.

[0024] Last but not least, it is advantageous according to the invention to use hyaluronic acid as the polymer. The use of hyaluronic acid can further enhance the efficacy of the preparation against atopic dermatitis.

[0025] According to the invention, it is preferred if hyaluronic acid with a molecular weight of 3.0x10 is used as the polymer. 3 Up to 2.5x10 6 They are used there.

[0026] Furthermore, according to the invention, it is preferred if hyaluronic acid is used in a concentration of 0.05 to 0.15 wt%, based on the total weight of the preparation.

[0027] A particularly preferred embodiment of the present invention is characterized in that a combination of xanthan gum, gellan gum, tapioca starch, and hyaluronic acid is used as the polymers. In such a combination, it is further preferred according to the invention if hydroxypropyl guar is included as a further compound.

[0028] Advantageous embodiments of the present invention are further characterized in that one or more compounds selected from the group consisting of octyldodecanol, caprylic / capric triglycerides (INCI: Caprylic / Capric Triglyceride), dicaprylyl carbonate (INCI: Dicaprylyl Carbonate), grape seed oil (INCI: Vitis Vinifera Seed Oil), ... are used as lipids.

[0029] According to the invention, it is preferred if

[0030] Octyldodecanol at a concentration of 2 to 5% by weight, caprylic / capric triglycerides (INCI: Caprylic / Capric Triglycerides) at a concentration of 1 to 4% by weight,

[0031] Dicaprylyl carbonate (INCI: Dicaprylyl Carbonate) in a concentration of 1 to 3 wt% and

[0032] Grape seed oil (INCI: Vitis Vinifera Seed Oil) is used in a concentration of 0.01 to 1% by weight, based on the total weight of the preparation.

[0033] Advantageous embodiments of the present invention are also characterized in that the preparation contains ethanol.

[0034] In such a case, according to the invention, it is preferred if the preparation contains ethanol in a concentration of 5 to 12% by weight, based on the total weight of the preparation.

[0035] Particularly advantageous embodiments according to the invention are obtained when the preparation is free of polyacrylates, cross-linked acrylate / C10-C30 alkyl acrylate polymers, vinylpyrrolidone / hexadecene copolymers, 3-(4-methylbenzylidene) camphor, 2-hydroxy-4-methoxybenzophenone (INCI: oxybenzone), 4-methoxycinnamate-2-ethylhexyl ester (INCI: octyl methoxycinnamate), ethylhexyl-2-cyano-3,3-diphenyl acrylate (INCI: octocrylene), parabens (especially methyl, propyl and butyl paraben), methylisothiazolinone, chloromethylisothiazolinone, DMDM ​​hydantoin, mineral oils, mineral waxes and silicone oils.

[0036] However, according to the invention, it is advantageous if the preparation contains one or more active ingredients selected from the group of compounds glycyrrhetinic acid, urea, arctiin, alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, caffeine, natural and / or synthetic isoflavonoids, glyceryl glucose, creatine, creatinine, taurine, β-alanine and / or licochalcone A, panthenol, tocopherol, tocopherol acetate, glycyrrhiza inflata root extract.

[0037] Furthermore, advantageous embodiments according to the invention are characterized in that the preparation contains one or more active ingredients selected from the group of compounds hydroxyacetophenone and decylene glycol. The combination of both components is preferred according to the invention.

[0038] Last but not least, the treatment method according to the invention is characterized in that the preparation is applied to the skin in an amount of 0.005 grams to 1 gram per square centimeter.

[0039] Proof of effectiveness

[0040] The following recipe was examined in a consumer study:

[0041] A panel of 106 participants (50% women, 50% men, all over 18 years of age) with moderate atopic dermatitis (no flare-up phase or cortisone treatment) applied the preparation at least three times per week in an in-home use test. After two and four weeks of use, the participants were surveyed about the product using a questionnaire. The following agreement rates were obtained for the following questions: Examples

[0042] The following examples are intended to illustrate the present invention without limiting it. Unless otherwise stated, all quantities, proportions, and percentages are based on the weight and total quantity or total weight of the preparations.

Claims

1. Containing oil-in-water emulsion (O / W emulsion) 70 to 80% by weight, based on the total weight of the preparation, water, 5 to 10% by weight, based on the total weight of the preparation, lipids, 2 to 8% by weight, based on the total weight of the preparation, glycerin, one or more emulsifiers, one or more polymers, for the cosmetic and / or dermatological treatment of atopic dermatitis.

2. O / W emulsion according to claim 1, characterized in that sodium cetearyl sulfate (INCI: Sodium Cetearyl Sulfate) is used as the emulsifier.

3. O / W emulsion according to one of the preceding claims, characterized in that sodium cetearyl sulfate is used as the emulsifier in a concentration of 0.03 to 0.08 wt%, based on the total weight of the preparation.

4. O / W emulsion according to one of the preceding claims, characterized in that one or more compounds selected from the group of gums (INCI: Gums) are used as polymers.

5. O / W emulsion according to claim 4, characterized in that xanthan gum (INCI: Xanthan Gum) and / or gellan gum (INCI: Gellan Gum) is used as gum.

6. O / W emulsion according to one of the preceding claims, characterized in that the preparation contains gums in a total concentration of 0.1 to 0.5 wt. %, based on the total weight of the preparation.

7. O / W emulsion according to one of the preceding claims, characterized in that one or more starches are used as polymers.

8. O / W emulsion according to one of the preceding claims, characterized in that one or more starches are used as polymers in a total concentration of 1 to 2 wt%, based on the total weight of the preparation.

9. O / W emulsion according to one of the preceding claims 7 and 8, characterized in that tapioca starch (INCI: Tapioca Starch) is used as the starch.

10. O / W emulsion according to one of the preceding claims, characterized in that hyaluronic acid is used as the polymer.

11. O / W emulsion according to one of the preceding claims, characterized in that the polymers are hyaluronic acid with a molecular weight of 3.0x10 3 Up to 2.5x10 6 is used.

12. O / W emulsion according to one of the preceding claims, characterized in that hyaluronic acid is used as the polymer in a concentration of 0.05 to 0.15 wt%, based on the total weight of the preparation.

13. O / W emulsion according to one of the preceding claims, characterized in that a combination of xanthan gum, gellan gum, tapioca starch and hyaluronic acid is used as polymers.

14. O / W emulsion according to one of the preceding claims, characterized in that one or more compounds selected from the group consisting of octyldodecanol, caprylic / capric triglycerides (INCI: Caprylic / Capric Triglyceride), dicaprylyl carbonate (INCI: Dicaprylyl Carbonate), grape seed oil (INCI: Vitis Vinifera Seed Oil), ... are used as lipids.

15. O / W emulsion according to one of the preceding claims, characterized in that the preparation contains ethanol.

16. O / W emulsion according to one of the preceding claims, characterized in that the preparation contains ethanol in a concentration of 5 to 12 wt%, based on the total weight of the preparation.

17. O / W emulsion according to one of the preceding claims, characterized in that the preparation is free of polyacrylates, cross-linked acrylate / C10-C30 alkyl acrylate polymers, vinylpyrrolidone / hexadecene copolymers, 3-(4-methylbenzylidene) camphor, 2-hydroxy-4-methoxybenzophenone (INCI: oxybenzone), 4-methoxycinnamate-2-ethylhexyl ester (INCI: octyl methoxycinnamate), ethylhexyl-2-cyano-3,3-diphenyl acrylate (INCI: octocrylene), parabens (in particular methyl, propyl and butyl paraben), methylisothiazolinone, chloromethylisothiazolinone, DMDM ​​hydantoin, mineral oils, mineral waxes and silicone oils.

18. O / W emulsion according to one of the preceding claims, characterized in that the preparation contains one or more active ingredients selected from the group of compounds glycyrrhetinic acid, urea, arctiin, alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, caffeine, natural and / or synthetic isoflavonoids, glyceryl glucose, creatine, creatinine, taurine, β-alanine and / or licochalcone A, panthenol, tocopherol, tocopherol acetate, glycyrrhiza inflata root extract.

19. O / W emulsion according to one of the preceding claims, characterized in that the preparation contains one or more active ingredients selected from the group of compounds hydroxyacetophenone and decylene glycol.

20. O / W emulsion according to one of the preceding claims, characterized in that the preparation is applied to the skin in an amount of 0.005 grams to 1 gram per square centimeter.

Images